Detalhe da pesquisa
1.
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience.
Pituitary
; 27(3): 303-309, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713317
2.
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype?
Int J Mol Sci
; 25(3)2024 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38339173
3.
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.
Int J Mol Sci
; 24(21)2023 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37958702
4.
Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience.
Pituitary
; 25(6): 831-841, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35922724
5.
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study.
BMC Geriatr
; 21(1): 598, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34702173
6.
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients.
Clin Endocrinol (Oxf)
; 88(5): 692-699, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29418012
7.
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Pituitary
; 21(3): 302-308, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29397538
8.
Correction to: Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Pituitary
; 21(3): 309, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29473124
9.
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis.
Pituitary
; 21(4): 414-424, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29752700
10.
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Prospective Single-Center Experience.
Neuroendocrinology
; 104(3): 280-290, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27165294
11.
Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry.
Clin Endocrinol (Oxf)
; 83(4): 527-35, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26119712
12.
Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Neuroendocrinology
; 101(2): 143-50, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25633744
13.
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review.
Pituitary
; 17(3): 267-76, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23828322
14.
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach.
Diagnostics (Basel)
; 14(3)2024 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38337790
15.
The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
J Clin Endocrinol Metab
; 109(5): 1341-1350, 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37975821
16.
Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences.
Drugs Context
; 132024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38817802
17.
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues.
Endocr Metab Immune Disord Drug Targets
; 2024 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38284724
18.
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis.
Endocr Connect
; 13(3)2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197875
19.
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case.
JCEM Case Rep
; 1(2): luad031, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37908471
20.
De-escalation treatment with pasireotide for acromegaly: a long-term experience.
Endocrine
; 80(3): 505-510, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36808072